Prodrug strategy for cancer cell-specific targeting: A recent overview
- 1 October 2017
- journal article
- review article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 139, 542-563
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81773571, 81603025, 81230078, 81573346)
- Natural Science Foundation of Jiangsu Province (BK20170088)
- Qing Lan’ Project of Jiangsu Province
- National Major Science and Technology Project of China (2015ZX09101032, 2017ZX09302003, 2017ZX09101004-003-006)
- Fundamental Research Funds for the Central Universities (2632017ZD03)
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
This publication has 125 references indexed in Scilit:
- Role of Glutathione in Cancer Progression and ChemoresistanceOxidative Medicine and Cellular Longevity, 2013
- NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinonesBiochemical Pharmacology, 2012
- Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugsBioorganic & Medicinal Chemistry, 2012
- Targeting Cell Surface Alpha(v)beta(3) Integrin Increases Therapeutic Efficacies of a Legumain Protease-Activated Auristatin ProdrugMolecular Pharmaceutics, 2011
- Hydrogen Peroxide Inducible DNA Cross-Linking Agents: Targeted Anticancer ProdrugsJournal of the American Chemical Society, 2011
- Prodrugs for improving tumor targetability and efficiencyAdvanced Drug Delivery Reviews, 2011
- Prodrug cancer gene therapyCancer Letters, 2008
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008
- Kinetic and Structural Characterisation of Escherichia coli Nitroreductase Mutants Showing Improved Efficacy for the Prodrug Substrate CB1954Journal of Molecular Biology, 2007
- ROS stress in cancer cells and therapeutic implicationsDrug Resistance Updates, 2004